AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02679768 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Reinforcement Therapy
Description: Circadian reinforcement therapy plus electronical monitoring. Circadian reinforcement therapy is a specialized psychoeducation working with strengthening of circadian rhythms.
Study NCT02679768 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment plus electronical monitoring
Study NCT03679585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Undergo Talking Pictures social media intervention
Study NCT03679585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03679585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01388920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Study NCT01388920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01775462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDI200
Description: 3 or 10 mg/kg of EDI200
Study NCT05319769 — intervention group
Intervention type: PROCEDURE
Intervention: Atrial fibrillation ablation
Description: Pulmonary vein isolation
Study NCT02467335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-663068
Description: BMS-663068
Study NCT02462083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: IDP-118 lotion will be applied as per the instructions provided by the investigational center staff.
Study NCT01361815 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: H-Coil Deep TMS in combination with SSRIs
Description: The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
Study NCT02711995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RenuGel
Description: Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
Study NCT02711995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
Study NCT04176614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cereal-legume snack
Description: cereal-legume biscuit
Study NCT04176614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cereal snack
Description: cereal biscuit
Study NCT02018861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Study NCT02018861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parsaclisib
Study NCT02018861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Study NCT02018861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Study NCT02018861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ifosfamide
Study NCT02018861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Study NCT02018861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Study NCT02272023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Motivational Interviewing
Description: Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
Study NCT02272023 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single session of Motivational Interviewing
Study NCT00115180 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04594954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet
Description: A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
Study NCT04594954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: A high-protein low carbohydrate diet (HPLC) diet would be prescribed to the patients. HPLC (high-protein low carbohydrate) diet would comprise of energy as 20-25 Kcal/Kg IBW/day (amounting to 700- 800 Kcal less than the usual dietary intake), Protein as 1.2-1.5 gm/Kg IBW/day i.e. 30% of the total calories as proteins, 52% of carbohydrates 18% of fats with dietary fiber as 25 g/day. The protein requirements would be met with modular high protein, low calorie supplements.
Study NCT04594954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: Stool Administration Procedure (ILBS FMT Protocol)~* 500 mL filtrates will be delivered through the UGI Endoscopy into proximal jejunum \[(2 to 3 minutes per 50 ml).\]~* The recipient will be kept nil per oral for at least 4 hours prior to the stool instillation.~* 100 mL freshly thawed sample will be given once in 15 days for 3 doses~* Non-absorbable antibiotics will be avoided in the patient from the time of enrollment into the study and therapy initiation.~* Intravenous antibiotics will be continued as per institutional protocol in the event of active sepsis based on culture and sensitivity.~* The patient will be allowed to consume liquid diet two hours after the procedure.
Study NCT04594954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min.
Study NCT04594954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical Activity:~The exercise program would consist of brisk walking. Brisk walking is defined as the walking intensity of 60-70% of their respective age-predicted maximum heart rate (target heart rate) 27,28. Speed of 5- 6 kmph considered as a brisk walking in most of the studies preferably on a treadmill for a duration of 30-45 minutes30 or brisk walking (walking faster than normal pace, measure 5000 steps continuously by pedometer). Same amount of physical activity would be prescribed to both the groups for 5 days a week for 30 -45 min.
Study NCT01733849 — intervention group
Intervention type: OTHER
Intervention: Stool sample
Description: Samples will be tested to determine the presence or absence of rotavirus.
Study NCT01733849 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Log books
Study NCT01539317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical liquid lidocaine
Description: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
Study NCT01539317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical liquid lidocaine
Description: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
Study NCT01539317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical saline
Description: saline applied to the vestibule mucosa will not reverse the local tenderness
Study NCT01539317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical saline
Description: saline applied to the vestibule mucosa will not reverse the local tenderness
Study NCT04461249 — intervention group
Intervention type: DRUG
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
Study NCT04461249 — intervention group
Intervention type: DRUG
Intervention: Travoprost 0.004% ophthalmic solution
Description: Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
Study NCT04461249 — intervention group
Intervention type: DRUG
Intervention: Tafluprost Ophthalmic 0.0015% Ophthalmic Solution
Description: Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
Study NCT04322214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat 150 MG
Description: once daily cobicistat (150 mg QD) for 5 days
Study NCT03066518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 5 mg
Study NCT03434691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis Probe (Muscle microdialysis)
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.
Study NCT04322214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once daily lactose capsules (as aspect cobicistat capsules)
Study NCT04322214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB
Description: single oral dose of GHB (25 mg/kg) on days 5 and 17
Study NCT03066518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03434691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis Probe (Muscle microdialysis)
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.
Study NCT00839202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FVIII immuno-assay
Description: There is no intervention. This is a study of the differences in assays.
Study NCT03294265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support sessions
Description: Stages of mourning and motivation Patients introduce themselves, share their experience and mention a strategy on moving on to the next stage Reminder of metabolic control goals Leaders write on the board metabolic variables and ask everybody the goal values. Patients share their results and mention plans to improve them Self-care activities Leaders ask who owns a glucometer, how regularly they use it, its importance and consequences of not doing so.~Simplified meal plan Everyone brings a snack. Leaders ask if each snack is appropriate, how everyone carries out their meal plan, barriers and possible strategies Activities to increase physical activity Everyone compares who achieves 10 thousand steps/day and who doesn't, then mention benefits of exercise
Study NCT03294265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders
Description: Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups.
Study NCT03294265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups.
Study NCT01691989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally once a day for 26 weeks
Study NCT01691989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral doses once a day for 26 weeks
Study NCT01409174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I.
Study NCT03434691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanyl
Description: Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
Study NCT03434691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanyl
Description: Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
Study NCT06183320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with Incremental Composite in Proximal Wall
Description: Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, proximal wall will be completely restored with Vittra APS composite resin, using the triangular incremental traditional technique described for classe II restorations. Then, Opus Bulk Fill Flow APS will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
Study NCT06183320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Bulk Fill Composite in Proximal Wall
Description: Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, Opus Bulk Fill Flow APS resin will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
Study NCT00003906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: 60 mg/day plus placebo for 5 years
Study NCT00003906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg/day plus placebo for 5 years
Study NCT01675973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RANEXA
Description: 500mg BID up to 1000mg BID
Study NCT01409174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200 mg/m\^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
Study NCT01409174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m\^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
Study NCT01409174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
Study NCT02439515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling
Description: Voluntary cycling augmented by electrical stimulation and biofeedback
Study NCT02439515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance control exercises with visual biofeedback
Study NCT02439515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy
Description: It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
Study NCT02439515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
Study NCT02188628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-Man
Description: H-man is a portable end-effector planar upper limb robot.
Study NCT04317742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Healthy Using the Internet (SHUTi) Intervention Group
Description: SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time.
Study NCT02188628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Conventional Therapy
Description: Repetitive goals based arm therapy
Study NCT02818296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active IU CBM-I
Study NCT02818296 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control CBM-I
Study NCT04823936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stability training
Description: core stability training program for 30 minutes including Supine abdominal draw in Abdominal draw in with double knee to chest Trunk twist while sitting on medical ball Lying supine on the medical ball and rotating the trunk to the sides Contracting abdominal muscles while lying in a supine position and pulling the limbs upward with arms and legs kept close Bringing up the arms and legs simultaneously in the prone position Bridging with head on medical ball hold this position for 3-5 s then slowly relaxes Bridging while shoulders and hands are on the floor and one leg is raised Lying supine on the medical ball and holding the abdomen in and bringing with one leg up
Study NCT04317742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online Patient Education (PE) Control Group
Description: The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
Study NCT02102802 — intervention group
Intervention type: DRUG
Intervention: Midomafetamine
Description: 125, 75, or 30 mg midomafetamine HCl followed 1.5 to 2 hours later by a supplemental dose of midomafetamine HCl half the initial dose
Study NCT02102802 — intervention group
Intervention type: BEHAVIORAL
Intervention: Therapy
Description: Manualized therapy
Study NCT01409174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 9 million IU/m\^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
Study NCT03302429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF/ BCP
Description: Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
Study NCT03302429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone graft
Description: Bone obtained from the same individual who receiving the graft
Study NCT03640624 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Description: 1. Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~2. Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~3. Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients.
Study NCT03640624 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)